{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:08:04Z","timestamp":1773835684687,"version":"3.50.1"},"reference-count":26,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hanmi Pharmaceutical Co. Ltd."},{"name":"Hanmi Pharmaceutical Co. Ltd."},{"name":"Soonchunhyang University Research fund"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second\u2010line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine\u2010refractory advanced pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      A multicenter phase II prospective open\u2010label, single\u2010arm study was conducted at 14 hospitals. Patients with histologically proven invasive ductal pancreatic adenocarcinoma, a measurable or evaluable lesion, Eastern Cooperative Oncology Group performance status 0 or 1, adequate organ function, and aged 19 years or older were eligible. Attenuated FOLFIRINOX consisted of oxaliplatin 65 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , irinotecan 135 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and leucovorin 400 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      injected intravenously on day 1 and 5\u2010fluorouracil 2000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      continuously infused intravenously over 46 h on days 1\u20132, repeated every 2 weeks. The primary endpoint was progression\u2010free survival from the initiation of FOLFIRINOX. Secondary endpoints were the objective response rate, disease control rate, overall survival, safety, and tolerability. We estimated overall survival and progression\u2010free survival using the Kaplan\u2013Meier methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">We enrolled 39 patients from 14 institutions. The objective response rate was 10.3%, while the disease control rate was 64.1%. The 6\u2010month and 1\u2010year overall survival rates were 59.0% and 15.4%, respectively. Median progression\u2010free survival and overall survival were 3.8 months (95% confidence interval [CI] 1.5\u20136.0 months) and 8.5 months (95% CI 5.6\u201311.4 months), respectively. Grade 3 or 4 adverse events were neutropenia (41.0%), nausea (10.3%), anorexia (10.3%), anemia (7.7%), mucositis (7.7%), pneumonia\/pleural effusion (5.1%), and fatigue (5.1%). One treatment\u2010related death attributable to septic shock occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p xml:lang=\"en\">Attenuated FOLFIRINOX may be promising as a second\u2010line therapy for gemcitabine\u2010refractory pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40880-018-0304-1","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T11:23:08Z","timestamp":1528111388000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Attenuated FOLFIRINOX in the salvage treatment of gemcitabine\u2010refractory advanced pancreatic cancer: a phase II study"],"prefix":"10.34133","volume":"38","author":[{"given":"Jung Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Gyeongsang National University","place":["Jinju, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang\u2010Cheol","family":"Lee","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Hospital Cheonan","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"Dong\u2010A University Hospital","place":["Busan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo\u2010Young","family":"Song","sequence":"additional","affiliation":[{"name":"Kangwon National University School of Medicine","place":["Chuncheon, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namsu","family":"Lee","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Hospital Seoul","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Mi","family":"Nam","sequence":"additional","affiliation":[{"name":"Ewha Womans University, College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonil","family":"Lee","sequence":"additional","affiliation":[{"name":"Dankook University Hospital","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Gyu","family":"Hwang","sequence":"additional","affiliation":[{"name":"Chung\u2010Ang University, College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Rak","family":"Lee","sequence":"additional","affiliation":[{"name":"Korea Cancer Hospital","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Taek","family":"Lee","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Hospital Cheonan","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang\u2010Byung","family":"Bae","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Hospital Cheonan","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Jo","family":"Kim","sequence":"additional","affiliation":[{"name":"Soonchunhyang University Hospital Cheonan","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joung Soon","family":"Jang","sequence":"additional","affiliation":[{"name":"Chung\u2010Ang University, College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Hyoung","family":"Lim","sequence":"additional","affiliation":[{"name":"Dankook University Hospital","place":["Cheonan, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Woo","family":"Lee","sequence":"additional","affiliation":[{"name":"Ajou University Hospital","place":["Suwon, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Yun","family":"Kang","sequence":"additional","affiliation":[{"name":"Ajou University Hospital","place":["Suwon, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[{"name":"Gyeongsang National University","place":["Jinju, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2002.17.5.611"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102354.2007.00818.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2010.25.8.1113"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.05.005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658\u2010199603000\u201000007"},{"key":"e_1_3_2_7_2","first-page":"120","article-title":"Survival analysis according to treatment modality in pancreatic cancer patients","volume":"46","author":"Jung SW","year":"2005","unstructured":"Jung SW, Park JY, Kim YS, Jeen YT, Lee HS, Chun HJ, et al. Survival analysis according to treatment modality in pancreatic cancer patients. Korean J Gastroenterol. 2005; 46: 120\u2013128.","journal-title":"Korean J Gastroenterol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4869"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2014.957188"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010012\u20101875\u20101"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605374"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010009\u20109265\u20101"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000356158"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6995"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds224"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000439171"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010014\u20104225\u20101"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12253\u2010016\u20100176\u20100"},{"key":"e_1_3_2_20_2","first-page":"814","article-title":"Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S\u20101 in Japan: a single institutional experience","volume":"61","author":"Umemura A","year":"2014","unstructured":"Umemura A, Nitta H, Sasaki A, Takahara T, Hasegawa Y, Wakabayashi G. Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S\u20101 in Japan: a single institutional experience. Hepatogastroenterology. 2014; 61: 814\u2013820.","journal-title":"Hepatogastroenterology"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Kobayashi N Shimamura T Tokuhisa M Goto A Endo I Ichikawa Y. Effect of FOLFIRINOX as second\u2010line chemotherapy for metastatic pancreatic cancer after gemcitabine\u2010based chemotherapy failure. Medicine (Baltimore). 2017;96. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5428587\/. Accessed 17 Dec 2017.","DOI":"10.1097\/MD.0000000000006769"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31829e2006"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.222"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju413"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016\u20100447"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.07.007"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-018-0304-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1186%2Fs40880-018-0304-1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1186\/s40880-018-0304-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:56:35Z","timestamp":1773824195000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1186\/s40880-018-0304-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1186\/s40880-018-0304-1"],"URL":"https:\/\/doi.org\/10.1186\/s40880-018-0304-1","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"2017-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"32"}}